Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T01232
(Former ID: TTDI01328)
|
|||||
| Target Name |
T-cells (T-cells)
|
|||||
| Synonyms |
T cells
Click to Show/Hide
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Transplant rejection [ICD-11: NE84] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 6 Clinical Trial Drugs | + | ||||
| 1 | ATG-Fresenius S | Drug Info | Phase 3 | Transplant rejection | [2] | |
| 2 | DiabeCell | Drug Info | Phase 2 | Insulin-dependent diabetes | [5] | |
| 3 | TVI-Kidney-1 | Drug Info | Phase 2 | Renal cell carcinoma | [6] | |
| 4 | BPX-501 | Drug Info | Phase 1/2 | Osteoporosis | [7] | |
| 5 | AX-024 | Drug Info | Phase 1 | Multiple sclerosis | [8] | |
| 6 | RTL-1000 | Drug Info | Phase 1 | Multiple sclerosis | [9] | |
| Mode of Action | [+] 4 Modes of Action | + | ||||
| Modulator | [+] 1 Modulator drugs | + | ||||
| 1 | DiabeCell | Drug Info | [1] | |||
| Immunomodulator | [+] 1 Immunomodulator drugs | + | ||||
| 1 | BPX-501 | Drug Info | [4] | |||
| Inhibitor | [+] 1 Inhibitor drugs | + | ||||
| 1 | AX-024 | Drug Info | [8] | |||
| Binder | [+] 1 Binder drugs | + | ||||
| 1 | RTL-1000 | Drug Info | [12] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
| REF 2 | ClinicalTrials.gov (NCT00655343) Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT). U.S. National Institutes of Health. | |||||
| REF 3 | ClinicalTrials.gov (NCT01693042) Compare the Effects of Single Versus Repeated Intracoronary Application of Autologous Bone Marrow-derived Mononuclear Cells on Mortality in Patients With Chronic Post-infarction Heart Failure. U.S. National Institutes of Health. | |||||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 5 | ClinicalTrials.gov (NCT01736228) Open-label Investigation of the Safety and Efficacy of DIABECELL in Patients With Type 1 Diabetes Mellitus. U.S. National Institutes of Health. | |||||
| REF 6 | Clinical pipeline report, company report or official report of TVAX Biomedical. | |||||
| REF 7 | ClinicalTrials.gov (NCT01744223) Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant. U.S. National Institutes of Health. | |||||
| REF 8 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 9 | ClinicalTrials.gov (NCT00411723) Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis. U.S. National Institutes of Health. | |||||
| REF 10 | Clinical pipeline report, company report or official report of Neovii Biotech. | |||||
| REF 11 | Clinical pipeline report, company report or official report of TVAX Biomedical. | |||||
| REF 12 | RTL THERAPY FOR MULTIPLE SCLEROSIS: A Phase I Clinical Study. J Neuroimmunol. 2011 February; 231(1-2): 7-14. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.